A regimen with caplacizumab, immunosuppression and plasma exchange prevents unfavorable outcomes in immune-mediated TTP
Coppo et al. Blood 2021; 137(6): 733–742.
Select your desired language:
English
German | Deutsch
Spanish | Español
French | Français
Italian | Italiano
Japanese | 日本語
Extra: Additional Content
Blood Podcast: Season 2, Episode 6
Featuring a discussion of the Coppo trial
Content © 2021 by The American Society of Hematology
Site provided by Springer Healthcare. Part of the Springer Nature Group.